Table 2.

Binding site and mechanism of action of SARS-CoV-2 specific mAbs discussed in this review.

Groups of Specific mAbs	Name	Binding Site and Mechanism of Action
MAbs isolated from SARS-CoV-2 patients	B5	SARS-CoV-2 RBD; partial competition with ACE2
	B38	SARS-CoV-2 RBD; complete competition with ACE2
	H2	SARS-CoV-2 RBD; no competition with ACE2
	H4	SARS-CoV-2 RBD; complete competition with ACE2
	EY6A	SARS-CoV-2 RBD and SARS-CoV RBD with lower affinity; site spatially separate from that of ACE2
MAbs that cross-neutralize SARS-CoV and SARS-CoV-2	47D11	SARS-CoV-2 and SARS-CoV RBD; conserved epitope in the RBD
	CR3022	SARS-CoV RBD and SARS-CoV-2 RBD with lower affinity; conserved epitope in the RBD. Do not neutralize SARS-CoV-2
MAbs that have received Emergency Use Authorization (EUA)	Bamlanivimab (LY-CoV555)	SARS-CoV-2 RBD; EUA revoked
	Casirivimab (REGN10933) and imdevimab (REGN10987) in a combined therapy	Non-overlapping epitopes of the SARS-CoV-2 RBD
	Bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) in a combined therapy	Different, but overlapping, epitopes of the SARS-CoV-2 RBD